Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-23T16:50:12.906Z Has data issue: false hasContentIssue false
  • English
  • Français

Aripiprazole in the Treatment of Pediatric Bipolar Disorder: A Systematic Chart Review

Published online by Cambridge University Press:  07 November 2014

Joseph Biederman ,
Mary Ann McDonnell ,
Janet Wozniak ,
Thomas Spencer ,
Megan Aleardi ,
Richard Falzone  and
Eric Mick
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Pediatric bipolar diorder is a serious neuropsychiatric disorder asociated with high levels of morbidity and disabilty.

Objective

This is a systematic chart review of all outpatient youth with the diagnosis of bipolar disorder and bipolar spectrum disorder treated with aripiprazole either alone or as add-on to ongoing treatments.

Method

Medical records were reviewed to identify all subjects with bipolar and bipolar spectrum disorder prescribed aripiprazole in our clinic. During the chart review, the Clinical Global Impression scale was completed by the treating clinicians to determine usefullness.

Results

Forty-one youths (mean age±SD: 11.4±3.5 years) with bipolar spectrum disorder who had been treated with aripiprazole were identified. These children received a mean daily dose of aripiprazole 16.0±7.9 mg over an average of 4.6 months. Using a Clinical Global Impression-Improvement scale score of <2 (very much/much improved) to define robust improvement, 71% showed improvement in manic symptoms. Treatment with aripiprazole was well tolerated.

Conclusion

This study suggests that aripiprazole may be a useful and well-tolerated treatment for youth with bipolar disorder and it supports the need for controlled clinical trials of this compound in juvenile mania.

Type
Orginal Reasearch
Information
CNS Spectrums , Volume 10 , Issue 2 , February 2005 , pp. 141 - 148
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Biederman, J, Mick, E, Faraone, SV, Spencer, T, Wilens, TE, Wozniak, J. Pediatric mania: a developmental subtype of bipolar disorder? Biol Psychiatry. 2000;48:458–466.Google Scholar
2.Geller, B, Craney, JL, Bolhofner, K, Nickelsburg, MJ, Williams, M, Zimerman, B. Two-year prospective follow-up of children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry. 2002;159:927–933.Google Scholar
3.Wozniak, J, Biederman, J, Kiely, K, et al.Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995;34:867–876.CrossRefGoogle ScholarPubMed
4.Lewinsohn, PM, Klein, DN, Seeley, JR. Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord. 2000;2(3 pt 2):281–293.CrossRefGoogle Scholar
5.Biederman, J, Faraone, S, Wozniak, J, et al.Further evidence of unique developmental phenotypic correlates of pediatric bipolar disorder: findings from a large sample of clinically referred preadolescent children assessed over the last 7 years. J Affect Disord. In press.Google Scholar
6.Keck, PE Jr, Versiani, M, Potkin, S, et al.Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741–748.CrossRefGoogle Scholar
7.Tohen, M, Jacobs, TG, Grundy, SL, et al.Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000;57:841–849.Google Scholar
8.Campbell, M, Adams, P, Perry, R, Spencer, EK, Overall, JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24:251–255.Google ScholarPubMed
9.Sachs, GS, Grossman, F, Ghaemi, SN, Okamoto, A, Bowden, CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146–1154.Google Scholar
10.Brecher, M, Huizar, K. Quetiapine monotherapy for acute mania associated with bipolar disorder. In: Abstracts of Fifth Annual International Conference on Bipolar Disorder. Pittsburgh, Penn: International Society for Bipolar Disorders; 2003;9–12.Google Scholar
11.Frazier, JA, Biederman, J, Tohen, M, et al.A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001;11:239–250.Google Scholar
12.Biederman, J. Open-label study of risperidone I children with bipolar disorder. Abstract presented at: annual meetiong of European College of Neuropsychology. 2003; Prague, Czech Republic.CrossRefGoogle Scholar
13.McConville, B, Carrero, L, Sweitzer, D, et al.Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol. 2003;13:75–82.Google Scholar
14.Findling, RL. Use of quetiapine in children and adolescents. J Clin Psychiatry. 2002;63(suppl 13):27–31.Google ScholarPubMed
15.McRae, A, Labbate, LA. Aripiprazole: the latest antipsychotic. Intern Drug Ther Newsletter. 2003;38:25–34.Google Scholar
16.Micromedex Healthcare Series. Greenwood Village, Col: Thomson MICROMEDEX; 1974–2000.Google Scholar
17.Keck, PJ, Marcus, R, Tourkodimitris, S, et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651–1658.Google Scholar
18.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
19.Conners, CK, Barkley, RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull. 1985;21:809–843.Google Scholar
20.Biederman, J, Mick, E, Bostic, J, et al.The naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review. J Clin Psychiatry. 1998;59:628–637.Google Scholar
21.Tohen, M, Zarate, CA Jr, Centorrino, F, Hegarty, JI, Froeschl, M, Zarate, SB. Risperidone in the treatment of mania. J Clin Psychiatry. 1996;57:249–253.Google Scholar
22.Armenteros, JL, Whitaker, AH, Welikson, M, Stedge, DJ, Gorman, J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry. 1997;36:694–700.Google Scholar
23.McDougle, C, Holmes, J, Bronson, M, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36:685–693.Google Scholar
24.Quintana, U, Keshavan, M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1995;34:1292–1296.Google Scholar